LuxCath LLC has announced that the company's technology was used for the first time in procedures to treat arrhythmia patients.
According to the medical technology company, the ablation procedures were performed in eleven arrhythmia patients including atrial fibrillation patients in Prague at Homolka Hospital.
‘LuxCath, an Allied Minds company, announced this week the promising results of their new technology to treat arrhythmia patients.’
AdvertisementThe procedures were led by electrophysiologist Vivek Reddy, MD, Director of Arrhythmia Services at The Mount Sinai Hospital and the Mount Sinai Health System, and Petr Neuzil, MD, Director of Cardiology, Homolka Hospital.
The catheter-based technology can assess tissue contact, visualize lesions, and detect lesion gaps in real-time. LuxCath's technology has market applications in all arrhythmia ablation procedures and is being optimized for the treatment of Atrial Fibrillation.
"In all eleven patients, the technology identified tissue contact and was easy to use. In a wide variety of settings, we were able to assess and monitor ablation lesions as they were being created. There were no complications," said Vivek Reddy, MD. "This is an exciting step forward in the world of ablation. Based on our experience, the technology platform is quite promising."
"We are thrilled with the performance of our optical tissue interrogation system for contact and lesion progression assessment," said Dr. Omar Amirana, M.D., LuxCath Chief Executive Officer and Senior Vice President at its parent company, Boston-based Allied Minds. "Given the potential to positively impact all ablation procedures, we are excited to advance the technology into the marketplace. This is an enormous milestone for the company."
PHiberGene’s HG Swift Molecular Diagnostics Device Approved in Europe Magnesium Intake may be Beneficial in Preventing Pancreatic Cancer M
You May Also Like